Analysts Anticipate eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Will Announce Earnings of -$0.18 Per Share

Equities analysts expect eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) to report earnings per share of ($0.18) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for eFFECTOR Therapeutics’ earnings. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that eFFECTOR Therapeutics will report full-year earnings of ($0.52) per share for the current fiscal year, with EPS estimates ranging from ($0.54) to ($0.49). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.56) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow eFFECTOR Therapeutics.

eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last announced its earnings results on Wednesday, March 16th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.69. The firm had revenue of $0.31 million during the quarter.

EFTR has been the topic of a number of recent research reports. Credit Suisse Group cut their price objective on eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Thursday, March 17th. Zacks Investment Research raised eFFECTOR Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Friday. JMP Securities reissued a “buy” rating and issued a $8.00 target price on shares of eFFECTOR Therapeutics in a report on Monday, April 11th. Finally, Stifel Nicolaus lowered eFFECTOR Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $20.00 to $6.20 in a report on Tuesday, January 25th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $16.78.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC acquired a new stake in shares of eFFECTOR Therapeutics during the first quarter worth about $2,744,000. SR One Capital Management LP acquired a new stake in shares of eFFECTOR Therapeutics during the fourth quarter worth about $56,487,000. Geode Capital Management LLC boosted its stake in shares of eFFECTOR Therapeutics by 299.1% during the fourth quarter. Geode Capital Management LLC now owns 95,801 shares of the company’s stock worth $793,000 after buying an additional 71,796 shares during the period. Alps Advisors Inc. acquired a new stake in shares of eFFECTOR Therapeutics during the fourth quarter worth about $430,000. Finally, Northern Trust Corp acquired a new stake in shares of eFFECTOR Therapeutics during the fourth quarter worth about $138,000. Institutional investors own 51.71% of the company’s stock.

Shares of eFFECTOR Therapeutics stock traded down $0.14 during trading hours on Friday, reaching $1.80. 58,216 shares of the company were exchanged, compared to its average volume of 16,504. eFFECTOR Therapeutics has a 1 year low of $1.75 and a 1 year high of $40.42. The stock’s fifty day moving average is $3.66 and its 200 day moving average is $5.84. The company has a quick ratio of 13.30, a current ratio of 18.38 and a debt-to-equity ratio of 0.75.

eFFECTOR Therapeutics Company Profile (Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

Recommended Stories